Protalix BioTherapeutics, Inc. (PLX) Income Statement
PLX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPLX revenue and net income
Where PLX's revenue goes
2025Each bar shows an amount and its share of revenue. PLX kept −12.5% of revenue as net income.
PLX profit margins
PLX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −1.2% | +3.5% | −3.5% | +28.3% |
| Gross profit | −13.2% | −3.5% | −13.5% | +21.4% |
| Operating income | −240.4% | — | — | — |
| Net income | −325.2% | — | — | — |
| EPS (diluted) | −533.3% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PLX quarterly EPS vs estimates
Protalix BioTherapeutics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.02).
PLX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M | $34.2M | $21.1M | $9.2M |
| Cost of revenue | $27.5M | $24.3M | $23.0M | $19.6M | $16.3M | $10.9M | $10.9M | $9.3M | $15.2M | $8.4M |
| Gross profit | $25.2M | $29.1M | $42.5M | $28.0M | $22.0M | $52.0M | $43.8M | $24.9M | $5.8M | $801,000 |
| Research & development | $19.1M | $13.0M | $17.1M | $29.3M | $29.7M | $38.2M | $44.6M | $33.3M | $28.8M | $30.4M |
| Sales, general & admin | $11.7M | $40.8M | $25.5M | $13.6M | $4.0M | $5.1M | $6.0M | $10.9M | $11.5M | $9.4M |
| Total operating expenses | $30.7M | $25.2M | $32.1M | $41.1M | $42.5M | $49.3M | $54.5M | $44.2M | $40.4M | $34.0M |
| Operating income | −$5.5M | $3.9M | $10.5M | −$13.0M | −$20.5M | $2.7M | −$10.7M | −$19.3M | −$34.5M | −$33.2M |
| Interest income | $1.1M | $1.3M | $1.3M | $1.1M | $401,000 | $438,000 | $407,000 | $536,000 | $188,000 | $589,000 |
| Interest expense | $1.2M | $1.1M | $3.2M | $2.5M | $7.5M | $9.7M | $8.0M | $7.7M | $9.7M | $4.2M |
| Income before taxes | −$5.6M | $4.2M | $8.6M | −$14.4M | −$27.6M | −$6.5M | −$18.3M | −$26.5M | −$83.4M | −$29.2M |
| Income taxes | $996,000 | $1.2M | $254,000 | $530,000 | $6.4M | $8.4M | $8.0M | $536,000 | $7.8M | $10.9M |
| Net income | −$6.6M | $2.9M | $8.3M | −$14.9M | −$27.6M | −$6.5M | −$18.3M | −$26.5M | −$83.4M | −$29.4M |
| EBITDA | −$3.0M | $6.5M | $12.9M | −$10.8M | −$18.9M | $4.5M | −$8.7M | −$17.1M | −$71.8M | −$23.0M |
| EPS (diluted) | −$0.13 | $0.03 | $0.06 | −$0.30 | −$0.63 | −$0.16 | −$1.19 | −$2.77 | −$3.08 | −$3.97 |
| Gross margin | 47.8% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% | 80.1% | 72.8% | 27.7% | 8.7% |
| Operating margin | −10.4% | 7.3% | 16.0% | −27.3% | −53.4% | 4.3% | −19.6% | −56.4% | −163.8% | −360.5% |
| Net margin | −12.5% | 5.5% | 12.7% | −31.3% | −71.9% | −10.4% | −33.4% | −77.3% | −395.9% | −319.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.9M | $33.8M | $9.1M | $17.9M | $15.7M | $10.1M | $18.2M | $18.0M | $13.5M | $3.7M | $10.5M | $10.3M |
| Cost of revenue | $7.8M | $4.1M | $4.6M | $8.3M | $5.9M | $8.2M | $3.9M | $8.4M | $9.5M | $2.6M | $8.9M | $4.9M |
| Gross profit | $12.1M | $29.6M | $4.5M | $9.5M | $9.8M | $1.9M | $14.3M | $9.6M | $4.0M | $1.1M | $1.6M | $5.5M |
| Research & development | $4.4M | $5.4M | $5.6M | $4.5M | $6.0M | $3.5M | $4.1M | $3.0M | $3.0M | $2.9M | $3.1M | $3.7M |
| Sales, general & admin | $3.1M | $4.4M | $3.5M | $2.9M | $2.6M | $2.6M | $15.8M | $15.2M | $9.8M | $562,000 | $19.5M | $6.5M |
| Total operating expenses | $7.5M | $8.5M | $9.2M | $7.4M | $8.6M | $6.1M | $7.1M | $5.6M | $6.4M | $6.0M | $7.2M | $7.3M |
| Operating income | $4.7M | $21.1M | −$4.7M | $2.1M | $1.2M | −$4.1M | $7.2M | $4.0M | −$2.4M | −$4.9M | −$5.6M | −$1.9M |
| Interest income | $682,000 | $188,000 | $265,000 | $288,000 | $272,000 | $419,000 | $113,000 | $151,000 | $522,000 | $513,000 | $37,000 | $168,000 |
| Interest expense | $494,000 | $193,000 | $383,000 | $180,000 | $783,000 | $6,000 | $6,000 | $299,000 | $367,000 | $390,000 | $774,000 | $460,000 |
| Income before taxes | $4.9M | $21.1M | −$4.8M | $2.2M | $661,000 | −$3.7M | $7.3M | $3.8M | −$2.3M | −$4.7M | −$6.4M | −$1.7M |
| Income taxes | $1.1M | $2.8M | $728,000 | −$116,000 | $497,000 | −$113,000 | $822,000 | $607,000 | −$69,000 | −$138,000 | −$382,000 | $133,000 |
| Net income | $3.8M | $18.3M | −$5.5M | $2.4M | $164,000 | −$3.6M | $6.5M | $3.2M | −$2.2M | −$4.6M | −$6.0M | −$1.9M |
| EBITDA | $5.8M | $21.7M | −$4.0M | $2.8M | $1.8M | −$3.4M | $7.7M | $4.5M | −$1.6M | −$4.0M | −$5.3M | −$954,000 |
| EPS (diluted) | $0.05 | $0.22 | −$0.07 | $0.03 | −$0.04 | −$0.05 | $0.09 | $0.03 | −$0.03 | −$0.06 | −$0.07 | −$0.03 |
| Gross margin | 61.0% | 87.8% | 49.4% | 53.4% | 62.5% | 19.1% | 78.7% | 53.4% | 29.8% | 30.6% | 15.5% | 52.7% |
| Operating margin | 23.5% | 62.7% | −51.1% | 11.9% | 7.5% | −41.0% | 39.6% | 22.2% | −18.0% | −129.6% | −53.5% | −18.2% |
| Net margin | 19.0% | 54.3% | −60.3% | 13.2% | 1.0% | −35.8% | 35.6% | 18.0% | −16.4% | −122.6% | −57.6% | −17.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PLX's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PLX financial results
In fiscal year 2025 (ended December 31, 2025), Protalix BioTherapeutics reported revenue of $52.7 million, down 1.2% from the year before. It had a net loss of $6.6 million, a net profit margin of −12.5%. Diluted earnings per share came to −$0.13. Over five years revenue grew at an average rate of −3.5% a year.
See the PLX stock overview for the latest quote and news, or the PLX chart for price history and technical indicators.
PLX income statement FAQ
What is Protalix BioTherapeutics's annual revenue?
Protalix BioTherapeutics reported total revenue of $52.7 million for fiscal year 2025, which ended on December 31, 2025. That was down 1.2% from $53.4 million the previous year.
Is Protalix BioTherapeutics profitable?
No. Protalix BioTherapeutics reported a net loss of $6.6 million in fiscal 2025, a net profit margin of −12.5%; its operating margin was −10.4%.
What is Protalix BioTherapeutics's gross margin?
Protalix BioTherapeutics's gross margin was 47.8% in fiscal 2025: for every $100 of revenue, Protalix BioTherapeutics kept $48 after the direct cost of its products and services.
How much does Protalix BioTherapeutics spend on research and development?
Protalix BioTherapeutics spent $19.1 million on research and development in fiscal 2025, 36.1% of revenue.
How fast is Protalix BioTherapeutics growing?
Revenue grew −3.5% a year on average over the last five fiscal years, from $62.9 million to $52.7 million.
What are Protalix BioTherapeutics's earnings per share?
Protalix BioTherapeutics earned $-0.13 per diluted share in fiscal 2025, compared with $0.03 a year earlier.
When will Protalix BioTherapeutics report its next earnings?
Protalix BioTherapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Protalix BioTherapeutics's fiscal year end?
Protalix BioTherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.